Nilotinib-d3

• CAT Number: S000542
• CAS Number: 1215678-43-5
• Molecular Formula: C28H19D3F3N7O
• Molecular Weight: 532.53
• Purity: ≥95%
• IUPAC Name: 4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-N-[3-[4-(trideuteriomethyl)imidazol-1-yl]-5-(trifluoromethyl)phenyl]benzamide
• InChI: InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)/i2D3
• InChIKey: HHZIURLSWUIHRB-BMSJAHLVSA-N
• SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

Nilotinib-d3（Cat No.:S000542） is a deuterated form of nilotinib, where three hydrogen atoms are replaced with deuterium. Nilotinib is a targeted anticancer drug used primarily to treat chronic myelogenous leukemia (CML), especially in cases where patients are resistant to earlier-line treatment with imatinib. The incorporation of deuterium into nilotinib-d3 increases the molecule’s metabolic stability, potentially altering its pharmacokinetic properties. This can be valuable in research to better understand how nilotinib is metabolized and absorbed in the body, ultimately helping to optimize dosing and reduce side effects for more effective patient treatment strategies.